U
PDLI

UBS’s PDL BioPharma, Inc. PDLI Stock Holding History

UBS’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$24K Sell
3,200
-3,600
-53% -$33.4K ﹤0.01% 7801
2014
Q2 		$66K Sell
6,800
-1,100,300
-99% -$9.81M ﹤0.01% 6501
2014
Q1 		$9.2M Buy
1,107,100
+4,200
+0.4% +$36K 0.01% 1328
2013
Q4 		$9.31M Buy
1,102,900
+3,300
+0.3% +$27.8K 0.01% 1304
2013
Q3 		$8.76M Buy
1,099,600
+1,098,600
+109,860% +$8.83M 0.01% 1236
2013
Q2 		$8K Buy
+1,000
New +$7.8K ﹤0.01% 8944

Other funds holding PDLI

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS's PDLI Position: Q3 2014 in Review

UBS reduced its PDL BioPharma, Inc. (PDLI) stake by 62% in Q3 2014, selling an estimated $489K and leaving 32,132 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #5000.

UBS first reported a position in PDLI in Q2 2013 and has held it in 6 quarters since. The position peaked at $820K in Q2 2014. 231 funds tracked by Wall St. Rank hold PDLI as of Q3 2014.

  • UBS held 32,132 shares of PDL BioPharma, Inc. worth $240K as of Q3 2014.
  • UBS sold 52,634 PDL BioPharma, Inc. shares in Q3 2014, an estimated $489K.
  • PDL BioPharma, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5000 holding.
  • UBS first reported a position in PDL BioPharma, Inc. in Q2 2013 and has held it in 6 quarters since.
  • UBS's PDL BioPharma, Inc. position peaked at $820K in Q2 2014.
  • 231 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.